Urinary testosterone as a marker of risk of recurrence in operable breast cancer Paola BalleriniSaro OrianaGiorgio Secreto Report Pages: 1 - 6
Introduction C. F. LeMaistre Dose-intensive therapy — applications in breast cancer (Mini-symposium) Pages: S1 - S1
Quantitative immunohistochemical determination of cathepsin-D and its relation with other variables Silvia VeneroniMaria Grazia DaidoneRosella Silvestrini Report Pages: 7 - 13
Design of preparative regimens for stem cell transplantation in breast cancer G. SpitzerD. AdkinsW. Velasquez Dose-intensive therapy — applications in breast cancer (Mini-symposium) Pages: S3 - S9
Inhibition of growth and appearance of estrogen-dependent rat mammary tumors by 10-propargylestr-4-ene-3,17-dione, an aromatase inhibitor S. J. ZimniskiM. E. BrandtD. Puett Report Pages: 15 - 21
Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin, and BCNU in patients with breast cancer Roy B. JonesSteven MatthesElizabeth J. Shpall Dose-intensive therapy — applications in breast cancer (Mini-symposium) Pages: S11 - S17
Differential expression of steroid receptors, hsp27, and pS2 in a series of drug resistant human breast tumor cell lines derived following exposure to antitumor drugs or to fractionated X-irradiation Richard D. H. WhelanBridget T. Hill Report Pages: 23 - 39
New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation Elizabeth J. ShpallSalomon M. StemmerRoy B. Jones Dose-intensive therapy — applications in breast cancer (Mini-symposium) Pages: S19 - S23
Epidermal growth factor-like activity and epidermal growth factor-receptors in human primary breast cancer Zsuzsanna KahánMária SzücsSándor Eckhardt Report Pages: 41 - 47
Application of peripheral blood progenitors to dose-intensive therapy of breast cancer Stephanie F. Williams Dose-intensive therapy — applications in breast cancer (Mini-symposium) Pages: S25 - S29
Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C W. ScheithauerG. KornekD. Depisch Report Pages: 49 - 53
Autologous graft-versus-host disease: immunotherapy of breast cancer after bone marrow transplantation M. John KennedyRichard J. Jones Dose-intensive therapy — applications in breast cancer (Mini-symposium) Pages: S31 - S40
Relationship between immunological parameters and survival of patients with liver metastases from breast cancer given immuno-chemotherapy Seiji YamasakiNorimichi KanKazuhisa Ohgaki Report Pages: 55 - 65
DNA ploidy and helix pomatia lectin binding as predictors of regional lymph node metastases and prognostic factors in breast cancer Masakuni NoguchiMichael ThomasYuji Mizukami Report Pages: 67 - 75
Evaluation of lymphocyte immunity in breast cancer patients Jonathan F. HeadRobert L. ElliottJames L. McCoy Report Pages: 77 - 88
Tumour cyclic AMP binding proteins: an independent prognostic factor for disease recurrence and survival in breast cancer W. R. MillerD. M. A. WatsonR. A. Elton Report Pages: 89 - 94
Relationship between 90-kilodalton heat shock protein, estrogen receptor, and progesterone receptor in human mammary tumors G. ShyamalaM. SchweitzerS. J. Ullrich Report Pages: 95 - 100
The effect of tamoxifen on the endometrium Beatrice UzielyAbi LewinShlomo Mor-Yosef Brief communication Pages: 101 - 105
Response to P.M. Ravdin (BCRT 24:219-226, 1993), “Evaluation of cathepsin D as a prognostic factor in breast cancer” Henri RochefortSusan Thorpe Correspondence Pages: 107 - 111
